Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
A phase 3 trial of Histrelin in Prostate cancer, run by Endo USA Inc., a Keenova Therapeutics Company, completed.
Overview
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01697384 by Endo USA Inc., a Keenova Therapeutics Company, with 138 participants recorded, started 2000-04 and reaching its primary completion in 2003-08. Interventions recorded: histrelin acetate. Conditions recorded: Prostate Cancer, Adenocarcinoma of the Prostate.
Linked to the drug Histrelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Histrelin Subdermal Implant in Patients With Prostate Cancer
Shares Histrelin, Endo (now Keenova Therapeutics and Par Health), Prostate cancer and the tag pipeline.
- TrialMulti-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Shares Endo (now Keenova Therapeutics and Par Health) and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Histrelin, Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Histrelin, Prostate cancer and the tag pipeline.